20|20 OptimEyes Technologies

Breakthrough Drug Delivery for Mucosal Surfaces Improving Patient Outcomes

Investment Opportunity

Building on over $2M invested, we are **now raising $1M** to reach key valuation inflection points — including First-in-Human clinical testing for OPT-101 and preclinical validation of our MNP platform across multiple indications & mucosal tissues

Platform Proof of Concept $400K

Generate data across 5 drug classes: encapsulation, extended release, and PK

Fund two full-time scientists to define the API design space

Conduct preliminary toxicology for top candidates

CMC Acceleration $450K

Parallelize CDMO work to support First-in-Human study of **OPT-101** (505(b)(2) glaucoma lead asset)

Complete formulation and scale-up for **OPT-201** (Dry Eye Disease in Dogs)

Scale-up manufacturing and qualify analytical methods

Strategic Partnering $150K

Expand out-licensing outreach to pharma, animal health, and oncology partners

Develop investor materials, valuation model and data room

Position for a $5–8M Series A in 2026

Outcomes of Investment



Proven Platform

Demonstrated compatibility with multiple APIs and indications

Clinical Acceleration

Completed **OPT-101 FIH**; enables shorter clinical pathways for subsequent indications

Commercial Readiness

Enable short term revenue generation through partnerships and early stage out-licensing

Capital Efficiency

Achieve major inflection points with a minimal raise

Leadership Team

F. Lasowski, PhD
CEO

15 Years Experience leading translational biomaterials research into pharma innovation

R. Jacquemart, PhD, MBA
COO

25 Years Experience with biopharma product development & commercialization

H. Sheardown, PhD
CSO

30 Years Experience with biomaterials & drug delivery research and development

+1 905-978-9262 frances@2020optimeyes.ca 2020optimeyes.ca Hamilton, Canada

20|20 OptimEyes Technologies

OptimEyes' MNP platform delivers small-molecule drugs directly to mucosal surfaces via a mucoadhesive polymer system that enables sustained, localized drug release. This approach improves bioavailability, compliance and safety, and supports topical delivery for multiple indications. The technology is applicable to all mucosal surfaces, across ophthalmology, respiratory, urogenital, gastrointestinal, oncology and CNS pathologies.

Patented Polymer Technology



Proprietary Polymer | Hydrophobic Drug | Mucoadhesive NanoParticles

Platform Benefits

Compatible
with a wide range of small-molecule APIS

Scalable
manufacturing with modular CMC approach

De-Risked
regulatory pathway enabling speed & IP extensions

Low COGS
with simple supply chain

We transform proven molecules into next-generation therapies through localized, sustained delivery – unlocking opportunities across all mucosal surfaces

MNPs



Enable sustained release through encapsulation

Mucosal Binding



Polymeric MNPs adhere to mucosal surfaces

Localized Delivery
Delivered directly to the site of action to reduce off-target side effects

Reduced Dosing Frequency
Sustained release enabling fewer administrations, improved patient compliance and convenience

Greater Bioavailability at Target
Greater drug loading and prolonged surface interaction give more drug at the target tissue

Key Data & Milestones Achieved

- Clear IP position based on novel polymer and formulation methods
- Regulatory plan confirmed in preliminary consultations
- **Pre-clinical safety** and glaucoma **efficacy** in canine
- Validated **encapsulation, extended release** and **pre-clinical studies** on 3 APIs
- **CDMO** contracted: tech transfer for gmp manufacturing in preparation
- Glaucoma Clinical site and protocol for FiH study selected

Broad Applicability



+1 905-978-9262 | frances@2020optimeyes.ca | 2020optimeyes.ca | Hamilton, Canada